Ras and Cancer in the 21st Century

Click to Enlarge				Ras and Cancer in the 21st Century Book Series: A Cold Spring Harbor Perspectives in Medicine Collection Subject Area(s): Cell Biology Edited by Linda Van Aelst, Cold Spring Harbor Laboratory; Julian Downward, The Francis Crick Institute; Frank McCormick, University of California, San Francisco

				Due July 2018 • 250 pages (approx.), illustrated, index Hardcover • ~~$135~~ 94.50 ISBN 978-1-621822-21-9 You save: 30% You will receive free shipping on this item at checkout. Free shipping offer applies to direct website purchases by individual U.S. and Canada customers only.

Description Contents Description Ras proteins are key molecular switches in cell signaling pathways that, when activated, trigger cell growth and division. Mutations that produce abnormally active Ras proteins are common in human cancers, particularly those of the pancreas, lung, and colon. These cancers can be difficult to treat because Ras oncoproteins have long been considered “undruggable.” Written and edited by experts in the field, this collection from Cold Spring Harbor Perspectives in Medicine covers the recent progress that has been made in understanding Ras biology, how Ras activation leads to tumorigenesis, and ways in which oncogenic Ras signaling may be targeted therapeutically. The contributors review the biochemical characteristics of the different Ras isoforms (HRAS, KRAS, and NRAS), their main effectors and signaling pathways, and the mutations that lead to their constitutive activation. Recent work showing that some Ras oncoproteins may be effectively inhibited by small molecules is covered, as is work on alternative targets (e.g., enzymes that catalyze posttranslational modifications of Ras) and inhibitors (e.g., nucleic acids). The authors also discuss how organoids and mouse models are being used to study tumor progression and therapeutic efficacy. This volume is therefore essential reading for all cancer biologists, cell and molecular biologists, and pharmacologists concerned with understanding and treating Ras-driven cancers. Contents Preliminary The K-Ras, N-Ras, and H-Ras Isoforms: Unique Conformational Preferences and Implications for Targeting Oncogenic Mutants Jillian A. Parker and Carla Mattos KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer Andrew M. Waters and Channing J. Der Ras and MAPK Neal Rosen P13K: A Crucial Piece in the RAS Signaling Puzzle Agata Adelajda Krygowska and Esther Castellano From Ras to Rap and Back, A Journey of 35 Years Johannes L. Bos Targeting Ras with Macromolecules Dehua Pei, Kuangyu Chen, and Hui Liao Post-Translational Modifications of RAS Proteins Ian Ahearn, Mo Zhou, and Mark Philips Targeting the MAPK Pathway in RAS Mutant Cancers Sarah G. Hymowitz and Shiva Malek Ras-Mediated Activation of the Raf Family Kinases Elizabeth M. Terrell and Deborah K. Morrison GAP Structure Klaus Scheffzek Synthetic Lethal Vulnerabilities in KRAS-mutant Cancers Andrew J. Aguirre and William C. Hahn Mechanistic and Preclinical Insights from Mouse Models of Hematologic Cancer Characterized by Hyperactive Ras Anica Wandler and Kevin Shannon The Interdependent Activation of SOS and Ras Pradeep Bandaru, Yasushi Kondo, and John Kuriyan Genetically Engineered Mouse Models of K-RAS Driven Lung and Pancreatic Tumors: Validation of Therapeutic Targets Matthias Drosten, Carmen Guerra, and Mariano Barbacid Kras in Organoids Derek Cheng and David Tuveson Ras and the Plasma Membrane: A Complicated Relationship Yong Zhou, Priyanka Prakash, Alemayehu A. Gorfe, and John F. Hancock Kras and Tumor Immunity: Friend or Foe? Jane Cullis, Shipra Das, and Dafna Bar-Sagi Efforts to Develop KRAS Inhibitors Matthew Holderfield Nf1 Therapy Karen Cichowski MRAS: A Close but Understudied Member of the Ras family Lucy C. Young and Pablo Rodriguez-Viciana Index

Ras and Cancer in the 21st Century

Description

Contents